Enhertu

News

A US appeals court has reversed a 2023 decision that ordered Daiichi Sankyo to pay royalties on sales of cancer drug Enhertu to Seagen (now Pfizer).

News

AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.

News

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso.